ReviewCurrent rheumatology reports2016
Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.JCI insight · 2022Trial
- Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.Cell reports. Medicine · 2020Trial
- Immunological coagulation dual axis stratification identifies ultra high-risk phenotypes in systemic sclerosis.Frontiers in immunology · 2026Article
- M1 macrophages - unexpected contribution to tumor progression.Frontiers in immunology · 2025Review
- Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.The Journal of pathology · 2025Article
- The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension.Frontiers in immunology · 2024Review
- Shedding light on macrophage immunotherapy in lung cancer.Journal of cancer research and clinical oncology · 2023Review
- Identification of Mechanisms by Which Genetic Susceptibility Loci Influence Systemic Sclerosis Risk Using Functional Genomics in Primary T Cells and Monocytes.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- STAT6 suppression prevents bleomycin-induced dermal fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Mitochondrial DNA copy number in patients with systemic sclerosis.Frontiers in molecular biosciences · 2023Article
- VISTA is an activating receptor in human monocytes.The Journal of experimental medicine · 2021Article
- Endothelial-to-mesenchymal transition in systemic sclerosis.Clinical and experimental immunology · 2021Review
- Monocyte Differentiation into Destructive Macrophages on In Vitro Administration of Gingival Crevicular Fluid from Periodontitis Patients.Journal of personalized medicine · 2021Article
- New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.Expert opinion on investigational drugs · 2021Review
- Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.Scientific reports · 2021Article
- Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study.Advances in rheumatology (London, England) · 2021Article
- Identification of Potential ceRNA Network and Patterns of Immune Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease.Frontiers in cell and developmental biology · 2021Article
- Macrophage LAMTOR1 Deficiency Prevents Dietary Obesity and Insulin Resistance Through Inflammation-Induced Energy Expenditure.Frontiers in cell and developmental biology · 2021Article
- Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.Journal of clinical medicine · 2020Review
- Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of systemic sclerosis is still unknown, although immune cells, mainly macrophages/monocytes, may have an important role in initiating and/or perpetuating the disease. Macrophages and monocytes are often classified as pro-inflammatory M1 phenotype or classic activation and pro-fibrotic/anti-inflammatory M2 phenotype or alternative activation. In this review, we highlighted the most relevant research regarding the involvement of macrophages/monocytes in the pathogenesis of this complex disease.
Indexed as
Identifiers
26700912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.